Challenges in translating clinical guidelines into real-life practice for management of hepatocellular carcinoma in Taiwan

키워드

참고문헌 (7)

1. Tung-Hung Su, "Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Taiwan perspective", Clinical and Molecular Hepatology, 29(2), pp.230~241 (2023), 대한간학회
2. 김도영, "Utility of combining PIVKA-II and AFP in the surveillance and monitoring of hepatocellular carcinoma in the Asia-Pacific region", Clinical and Molecular Hepatology, 29(2), pp.277~292 (2023), 대한간학회
3. Hsieh ST, "Real-world results of immune checkpoint inhibitors from the Taiwan National Health Insurance Registration System", Eur Rev Med Pharmacol Sci, 25, pp.6548~6556 (2021)
4. Chen SC, "Anti-PD-1 combined sorafenib versus anti-PD-1 alone in the treatment of advanced hepatocellular cell carcinoma : a propensity score-matching study", BMC Cancer, 22, pp.55~ (2022)
5. Wu WC, "Lenvatinib combined with nivolumab in advanced hepatocellular carcinoma-real-world experience", Invest New Drugs, 40, pp.789~797 (2022)
6. Wu CJ, "Lenvatinib plus pembrolizumab for systemic therapy-naïve and-experienced unresectable hepatocellular carcinoma", Cancer Immunol Immunother, 71, pp.2631~2643 (2022)
7. Finn RS, "Primary results from the phase III LEAP-002 study : Lenvatinib plus pembrolizumab versus lenvatinib as first-line(1L)therapy for advanced hepatocellular carcinoma(aHCC)", Ann Oncol, 33(Suppl 7), pp.S1401~ (2022)

관련 논문AI추천